| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
TLX
Telix Pharmaceuticals Limited Unsponsored ADR
|
Sep 22, 2026 | BUY |
Strong Buy
+74.7% avg upside
2 analysts
|
— | · | · |
|
VKTX
Viking Therapeutics
|
Sep 22, 2026 | BUY |
Strong Buy
+103.3% avg upside
31 analysts
|
— | +0.0% | · |
|
CATX
Perspective Therapeutics
|
Sep 18, 2026 | BUY |
Strong Buy
+339.9% avg upside
24 analysts
|
— | -12.5% | · |
|
CRDF
Cardiff Oncology
|
Sep 14, 2026 | HOLD |
Buy
+753.6% avg upside
18 analysts
|
— | -5.3% | · |
|
CRBP
Corbus Pharmaceuticals
|
Sep 14, 2026 | BUY |
Strong Buy
+382.5% avg upside
20 analysts
|
— | -7.4% | · |
|
EXEL
Exelixis
|
Sep 11, 2026 | BUY |
Buy
-27.0% avg upside
34 analysts
|
— | +4.0% | · |
|
PYXS
Pyxis Oncology
|
Sep 09, 2026 | HOLD |
Strong Buy
+184.4% avg upside
15 analysts
|
— | -5.6% | · |
|
GPCR
Structure Therapeutics, Inc. Sponsored ADR
|
Sep 08, 2026 | BUY |
Strong Buy
+185.3% avg upside
17 analysts
|
— | -8.3% | · |
|
KYNB
Kyntra Bio
|
Aug 31, 2026 | HOLD |
Buy
+368.0% avg upside
16 analysts
|
— | -10.8% | · |
|
ELVN
Enliven Therapeutics
|
Aug 22, 2026 | BUY |
Strong Buy
+33.7% avg upside
16 analysts
|
— | -24.6% | · |
|
NKTR
Nektar Therapeutics
|
Aug 14, 2026 | BUY |
Strong Buy
+30.7% avg upside
26 analysts
|
— | -8.5% | · |
|
KLRA
Kailera Therapeutics, Inc.
|
Aug 12, 2026 | BUY |
Strong Buy
+300.7% avg upside
5 analysts
|
— | -31.0% | · |
|
ALT
Altimmune
|
Aug 12, 2026 | HOLD |
Strong Buy
+763.5% avg upside
20 analysts
|
— | +4.4% | · |
|
AVIR
Atea Pharmaceuticals
|
Aug 12, 2026 | BUY |
Strong Buy
+30.9% avg upside
6 analysts
|
— | +2.2% | · |
|
AARD
Aardvark Therapeutics, Inc.
|
Aug 12, 2026 | BUY |
Buy
+274.3% avg upside
12 analysts
|
— | -15.4% | · |
|
LNTH
Lantheus
|
Aug 08, 2026 | HOLD |
Buy
-18.9% avg upside
21 analysts
|
— | -1.0% | · |
|
BIOA
BioAge Labs, Inc.
|
Aug 06, 2026 | HOLD |
Strong Buy
+402.2% avg upside
9 analysts
|
— | -36.0% | · |
|
TNYA
Tenaya Therapeutics
|
Jul 29, 2026 | BUY |
Strong Buy
+1533.5% avg upside
11 analysts
|
— | -17.0% | · |
|
SKYE
Skye Bioscience
|
May 12, 2026 | BUY |
Strong Buy
+2749.6% avg upside
9 analysts
|
— | -72.9% | · |
|
ZLDPF
Zealand Pharma
|
Mar 06, 2026 | HOLD |
Buy
+90.8% avg upside
12 analysts
|
— | +5.5% | · |
|
ATNM
Actinium Pharmaceuticals
|
Dec 22, 2023 | HOLD |
Strong Buy
+474.1% avg upside
11 analysts
|
— | -75.7% | · |
|
BYSI
Beyondspring
|
Dec 01, 2021 | HOLD |
Hold
+951.0% avg upside
8 analysts
|
— | -88.4% | · |
|
GILD
Gilead Sciences
|
Feb 12, 2019 | BUY |
Strong Buy
-21.2% avg upside
66 analysts
|
— | +6.3% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.